Generate Biomedicines AI Drug Discovery Timeline

Generate Biomedicines designs protein drugs with generative AI it builds itself, and it now has an AI-engineered asthma antibody in Phase 3. Here is every dated move we could verify, and how far each result has been proven.

Presented By Our Partners

The short answer: Generate Biomedicines is a Flagship Pioneering company that trains its own generative models to design antibodies and other proteins, then tests them in its own lab. Its Chroma model was published in Nature in 2023, and its AI-optimized COVID-19 antibody GB-0669 was well tolerated in a 51-person first-in-human trial published in 2026. Its long-acting asthma antibody GB-0895 is in global Phase 3 studies, but no efficacy results have been reported, and it enters a field where one anti-TSLP drug is already approved.

Tier: 2, AI science lab
Own models: Yes. Chroma, a generative model for protein structures and sequences (PMID 37968394)
Own wet lab: Yes. The Chroma paper, written by Generate scientists, reports lab testing of 310 designed proteins
First health move: March 2021, when Flagship Pioneering named Mike Nally to lead Generate (the earliest dated move we could source)
Furthest result so far: Tested in people, Phase 1 (GB-0669, peer-reviewed). GB-0895 is in Phase 3 with no results yet
Tier 1 partners: None we could verify. Nvidia, the chip maker, which is outside our tier 1 list, backed the 2023 Series C

What Is Generate Biomedicines?

Generate Biomedicines is a Somerville, Massachusetts biotech that designs protein drugs, mainly antibodies, with generative AI models it trains itself. It was built by Flagship Pioneering and listed on Nasdaq in 2026, raising $400 million at $16 per share, according to pharmaphorum and Renaissance Capital. IPO Scoop reported that the stock fell in its Nasdaq debut.

Its core model is Chroma, described in Nature in November 2023 (PMID 37968394). Chroma samples new protein structures and sequences and can be steered toward shapes, symmetries or functions. Generate pairs that software with its own experiments and a clinical pipeline, and it also designs molecules for large drug companies: Amgen since January 2022 and Novartis since September 2024.

Its two named clinical programs are both antibodies. GB-0669 targets a conserved region of the SARS-CoV-2 spike protein and finished a first-in-human safety trial. GB-0895 blocks TSLP, a signal from the airway lining that drives inflammation, and is in two global Phase 3 studies in severe asthma. Funding is not efficacy: more than $2.9 billion in combined reported deal ceilings from Amgen and Novartis, plus the IPO proceeds, say nothing yet about whether these drugs work.

Generate Biomedicines Healthcare Timeline: Every Move Since 2021

Entries are newest first. Result rows carry an evidence level from our fixed scale; deals, funding and hires are marked Not a result.

Date	Move	Type	Evidence level	Source
Jul 14, 2026	First-in-human trial of GB-0669, an AI-optimized antibody against a conserved part of the SARS-CoV-2 spike, published: 51 healthy adults, well tolerated, half-life of 54 days.	Result	Tested in people, Phase 1	PMID 42446369
2026	Initial public offering on Nasdaq raised $400 million at $16 per share.	Funding	Not a result	pharmaphorum, Renaissance Capital
Dec 1, 2025	Announced global Phase 3 studies (SOLAIRIA-1 and SOLAIRIA-2) of GB-0895, a long-acting anti-TSLP antibody for severe asthma engineered with AI and designed for twice-yearly dosing.	Trial	Not a result	Generate Biomedicines via Newswire, ClinicalTrials.gov
Sep 2024	Multi-target collaboration with Novartis on protein therapeutics, worth more than $1 billion in potential payments as reported.	Partnership	Not a result	Fierce Biotech, Business Wire
Jan 2024	Expanded its Amgen collaboration, announced alongside a pipeline update at the J.P. Morgan Healthcare Conference.	Partnership	Not a result	Generate Biomedicines via BioSpace
Nov 2023	Chroma, Generate’s generative model for protein structures and sequences, published in Nature; the team tested 310 designed proteins in the lab.	Model	Peer-reviewed, Research tool	PMID 37968394
Sep 2023	Closed a $273 million Series C financing; Nvidia and Amgen were among the backers.	Funding	Not a result	Business Wire, Boursorama
Jan 2022	Multi-target, multi-modality research collaboration with Amgen, reported at up to $1.9 billion.	Partnership	Not a result	Amgen, GEN
Nov 18, 2021	Raised $370 million in a Series B, its first outside equity raise.	Funding	Not a result	TechCrunch, BioSpace
Mar 31, 2021	Flagship Pioneering named former Merck executive Mike Nally to lead Generate as CEO.	Hire	Not a result	Flagship Pioneering, Fierce Biotech

Generate Biomedicines’ Biggest Results, and How Far Each Has Been Proven

Generate’s strongest evidence is a peer-reviewed protein design model and one completed Phase 1 trial. Its Phase 3 program has not yet produced data.

Chroma protein design model. Peer-reviewed, Research tool. The Nature paper reports that 310 Chroma-designed proteins were made and tested, that they were highly expressed and folded, and that two crystal structures matched the designs with a backbone deviation of about 1.0 angstrom (PMID 37968394). All authors were Generate staff, so the result has not been independently replicated in that paper. What would prove it next: a drug candidate whose design traces to Chroma succeeding in the clinic, or outside groups reproducing its design success rates.

GB-0669 first-in-human trial. Tested in people, Phase 1. In a randomized, placebo-controlled trial of 51 healthy adults aged 18 to 55 (36 on drug, 15 on placebo), single intravenous doses up to 2,400 mg caused no dose-limiting toxicities, all adverse reactions were mild (grade 1 or 2), and the half-life was 54 days (PMID 42446369). Serum virus neutralization rose at 600 and 1,200 mg. Seventeen of the 19 authors list Generate as an affiliation, so this is a company-run study in a peer-reviewed journal. The antibody was optimized with AI rather than invented from scratch, and healthy volunteers cannot show whether it treats COVID-19. What would prove it next: the Phase 2 trial at 1,200 mg in immunocompromised people with COVID-19 that the authors say the data support.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

GB-0895 in Phase 3 for severe asthma. Announced, Phase 3. Generate announced global Phase 3 studies, SOLAIRIA-1 and SOLAIRIA-2, of this long-acting anti-TSLP antibody, which it says is engineered with AI for twice-yearly dosing (Generate release, AllSci). The target is already validated: a 2026 review in the Journal of Allergy and Clinical Immunology notes that tezepelumab is the only approved anti-TSLP drug and lists GB-0895 as one of 11 TSLP-targeting drugs in clinical development (PMID 42697279; most of its authors work for Amgen or AstraZeneca, which sell tezepelumab). So the question for GB-0895 is less whether blocking TSLP works than whether dosing twice a year matches an approved drug on asthma attacks. We found no published efficacy data for GB-0895, and reaching Phase 3 is a trial milestone, not a result. What would prove it next: the Phase 3 readouts on asthma attacks and lung function.

Who Generate Biomedicines Works With

Generate works with two large drug companies and is backed by Flagship Pioneering. Amgen signed a multi-target, multi-modality research collaboration in January 2022, reported by GEN at up to $1.9 billion, and expanded it in January 2024. Novartis signed a multi-target protein therapeutics deal in September 2024 that Fierce Biotech reported at more than $1 billion in potential payments. Those figures are deal ceilings, mostly milestones, not money already paid.

Tier 1 ties: we found no funding or partnership with OpenAI, Anthropic, Google, Microsoft or Meta that we could verify. Nvidia, an AI chip maker rather than a tier 1 lab, was among the backers of the $273 million Series C in 2023, according to Boursorama. Generate runs its own lab: the Chroma paper describes in-house testing of hundreds of designed proteins, which is what places it in tier 2 rather than among companies that only build on other firms’ models.

What to Watch Next

These are the measurable events that would move Generate’s evidence level.

Results from the SOLAIRIA-1 and SOLAIRIA-2 Phase 3 studies of GB-0895 in severe asthma, including asthma attack rates and how they compare with tezepelumab’s.
Start of a Phase 2 trial of GB-0669 at 1,200 mg in immunocompromised people with COVID-19.
A named development candidate, milestone payment or option exercise disclosed under the Amgen or Novartis collaborations.
Independent groups reproducing Chroma’s design success rates.
Pipeline and cash updates in Generate’s quarterly SEC filings, starting with its report for the quarter ended June 30, 2026.

Related: see how every lab is graded in our AI healthcare breakthroughs tracker, where AI-designed drugs stand in our status report on AI-designed drugs in human trials, the antibody design models of Chai Discovery, the AI lab biotech deal tracker and how we score evidence in the HYPE Index methodology.

What This Means for You

If you are a patient, no Generate drug is approved, and none can be prescribed today. People with severe asthma may see GB-0895 Phase 3 studies recruiting; ClinicalTrials.gov lists SOLAIRIA-1 and its sites. If you already take an approved biologic for asthma, a trial drug is not a reason to switch on your own. Joining a trial is never a guarantee of benefit, so discuss it with your doctor.

If you work in research or care, Chroma is a published model you can evaluate on its own terms, and GB-0669 has peer-reviewed human safety data from a company-run trial. For investors, GB-0895 is the value driver: its Phase 3 readout will say more about Generate than any AI benchmark. Treat partnership values as signals of interest, not evidence, until trial results arrive.

Compiled by Healthcare Discovery from company announcements, named news reports and PubMed. Every PMID on this page was checked against PubMed on October 28, 2026. Evidence levels follow the scale explained in our AI healthcare breakthroughs tracker. Healthcare Discovery uses AI research tools from several companies on this page, including OpenAI, Anthropic and Google models; no company listed reviewed or paid for this page.

What is Generate Biomedicines?

Generate Biomedicines is a Somerville, Massachusetts biotech created by Flagship Pioneering that designs protein drugs, mainly antibodies, with generative AI models it trains itself. It went public on Nasdaq in 2026 and has an asthma antibody, GB-0895, in Phase 3 studies.

What is Chroma from Generate Biomedicines?

Chroma is Generate’s generative AI model for designing new protein structures and sequences. It was published in Nature in November 2023. The team tested 310 Chroma-designed proteins in the lab and reported that they were highly expressed and folded, and two crystal structures closely matched the designs.

Has an AI-designed antibody from Generate been tested in people?

Yes. GB-0669, an antibody against COVID-19 that Generate optimized with AI, was tested in a randomized first-in-human trial of 51 healthy adults published in 2026. It was well tolerated and had a half-life of 54 days. That trial tested safety and drug levels, not whether it treats COVID-19.

Is Generate Biomedicines a public company?

Yes. Generate raised $400 million in a Nasdaq initial public offering at $16 per share in 2026. Before that it raised a $370 million Series B in 2021 and a $273 million Series C in 2023.

Who are Generate Biomedicines’ partners?

Amgen has worked with Generate since January 2022, in a collaboration reported at up to $1.9 billion and expanded in 2024, and Novartis since September 2024, in a deal reported at more than $1 billion. Nvidia backed its 2023 Series C. We found no verified partnership with OpenAI, Anthropic, Google, Microsoft or Meta.

Has an AI-designed drug been approved?

We know of none as of October 2026. Generate’s most advanced program, GB-0895 for severe asthma, is in Phase 3 studies with no results reported yet.

Sources

Ingraham JB, et al. Illuminating protein space with a programmable generative model. Nature, 2023. PMID 37968394
Borriello F, et al. Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix. The Journal of Infectious Diseases, 2026. PMID 42446369
Corren J, et al. Lessons learned from clinical trials of thymic stromal lymphopoietin inhibition. The Journal of Allergy and Clinical Immunology, 2026. PMID 42697279
pharmaphorum. Generate’s IPO gets over the line, raising $400m, 2026. pharmaphorum
Renaissance Capital. Asthma-focused AI biotech Generate Biomedicines prices IPO at $16 midpoint, 2026. Renaissance Capital
IPO Scoop. The IPO Buzz: Generate Biomedicines prices IPO at $16 mid-point and stock falls in Nasdaq debut, 2026. IPO Scoop
U.S. Securities and Exchange Commission. Generate Biomedicines, Inc. Form 10-Q for the quarter ended June 30, 2026. SEC
Generate Biomedicines via Newswire. Generate Biomedicines to initiate global Phase 3 studies of GB-0895, a long-acting anti-TSLP antibody for severe asthma engineered with AI, December 2025. Newswire
ClinicalTrials.gov. A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1), NCT07276724. ClinicalTrials.gov
AllSci. Generate:Biomedicines advances AI-engineered asthma antibody into global Phase 3 trials with twice-yearly dosing. AllSci
Fierce Biotech. Novartis inks $1B-plus biobucks deal with Flagship’s Generate, September 2024. Fierce Biotech
Business Wire. Generate Biomedicines announces multi-target collaboration with Novartis, September 2024. Business Wire
Generate Biomedicines via BioSpace. Generate Biomedicines fortifies leadership in generative AI with advancing clinical pipeline and expanded Amgen collaboration overviewed at the 42nd annual J.P. Morgan Healthcare Conference, January 2024. BioSpace
Business Wire. Generate:Biomedicines Announces Close of $273M Series C Financing, September 2023. Business Wire
Boursorama. Nvidia et Amgen soutiennent la levée de fonds de 273 millions de dollars de Generate Biomedicines, September 2023. Boursorama
Amgen. Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement, January 2022. Amgen
GEN. Amgen, Generate launch up to $1.9B protein therapeutics collaboration, January 2022. GEN
TechCrunch. Generate Biomedicines raises $370M Series B with a focus on protein-based drugs, November 2021. TechCrunch
BioSpace. Generate Biomedicines Announces First External Equity Raise of $370 Million, November 2021. BioSpace
Flagship Pioneering. Flagship Pioneering Expands Leadership Team with Appointment of Michael T. Nally as CEO-Partner, March 2021. Flagship Pioneering
Fierce Biotech. Flagship hires Merck veteran to lead AI drug discovery startup, March 2021. Fierce Biotech

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

No spam. Unsubscribe anytime. We respect your inbox.